TABLE 1.
Comparisons of clinical, pathologic, and treatment characteristics between patients with OPM and without OPM
| Characteristics | Breast cancer without OPM (N = 3,922) |
Breast cancer with OPM (N = 276) |
P value |
|---|---|---|---|
| Age at breast cancer diagnosis in years | .0004 | ||
| Median (range) | 54 (22–89) | 58 (22–88) | |
| Mean | 54.7 | 57.3 | |
| BMI | .7 | ||
| Median (range) | 27 (14–62) | 28 (18–56) | |
| Mean | 28 | 28.2 | |
| Race | .6a | ||
| White | 2,993 (76.3) | 221 (80.1) | |
| Black | 591 (15.1) | 34 (12.3) | |
| Hispanic | 253 (6.4) | 16 (5.8) | |
| Other | 85 (2.2) | 5 (1.8) | |
| Family history of cancer | .1a, b | ||
| No | 1,253 (95.1) | 124 (98.4) | |
| Yes | 65 (4.9) | 2 (1.6) | |
| Unknown | 2,604 | 150 | |
| First-degree relative with cancer | .3a, b | ||
| No | 1,268 (87.4) | 125 (90.6) | |
| Yes | 182 (12.6) | 13 (9.4) | |
| Unknown | 2,472 | 138 | |
| BRCA mutation | .001a, b | ||
| No | 54 (85.7) | 1 (16.7) | |
| Yes | 9 (14.3) | 5 (83.3) | |
| Not assessed | 3,859 | 270 | |
| Year of breast cancer diagnosis | <.0001 | ||
| 1979–1988 | 322 (8.2) | 58 (21.0) | |
| 1989–1998 | 1,114 (28.4) | 105 (38.1) | |
| 1999–2007 | 2,486 (63.4) | 113 (40.9) | |
| Clinical stage | .048 | ||
| 0 | 495 (12.6) | 32 (11.6) | |
| I | 2,264 (57.7) | 182 (65.9) | |
| II | 1,016 (25.9) | 53 (19.2) | |
| III | 147 (3.8) | 9 (3.3) | |
| Tumor histology | .3 | ||
| IDC ± DCIS | 2,922 (74.5) | 210 (76.1) | |
| ILC ± DCIS | 218 (5.6) | 10 (3.6) | |
| IDC + ILC | 172 (4.4) | 11 (4.0) | |
| DCIS | 437 (11.1) | 27 (9.8) | |
| Other | 173 (4.4) | 18 (6.5) | |
| Tumor grade | 0.1b | ||
| I | 450 (12.2) | 36 (14.8) | |
| II | 1,799 (48.8) | 128 (52.7) | |
| III | 1,435 (38.9) | 79 (32.5) | |
| Unknown | 238 | 33 | |
| Estrogen receptor status | .3b | ||
| Positive | 2,485 (71.8) | 171 (75.3) | |
| Negative | 974 (28.2) | 56 (24.7) | |
| Unknown | 463 | 49 | |
| Progesterone receptor status | .6b | ||
| Positive | 2,041 (61.0) | 133 (63.0) | |
| Negative | 1,305 (39.0) | 78 (37.0) | |
| Unknown | 576 | 65 | |
| Pathologic nodal status | .03 | ||
| Negative | 3,132 (79.9) | 235 (85.1) | |
| Positive | 790 (20.1) | 41 (14.9) | |
| 1–3 | 633 (80.1) | 31 (75.6) | .09 |
| ≥4 | 157 (19.9) | 10 (24.4) | |
| Type of surgery | <.0001 | ||
| Lumpectomy | 482 (12.3) | 45 (16.3) | |
| Lumpectomy + SLND | 1,743 (44.4) | 76 (27.5) | |
| Lumpectomy + ALND | 1,326 (33.8) | 139 (50.4) | |
| Lumpectomy + SLND + ALND | 371 (9.5) | 16 (5.8) | |
| Follow-up time | .0001c | ||
| Mean | 8.7 | 11.2 | |
| Median (range) | 7.2 (2–30.5) | 9.9 (2–30.4) | |
| Adjuvant chemotherapy | <.0001 | ||
| Yes | 1,359 (34.6) | 64 (23.2) | |
| No | 2,537 (65.4) | 212 (76.8) | |
| Adjuvant hormone therapy | .008 | ||
| Yes | 2,088 (53.2) | 124 (44.9) | |
| No | 1,834 (46.8) | 152 (55.1) | |
| Contralateral breast cancer | <.0001 | ||
| Yes | 372 (9.5) | 44 (16.0) | |
| No | 3,550 (90.5) | 231 (84.0) | |
| Local recurrence | .7a | ||
| Yes | 235 (6.0) | 18 (6.5) | |
| No | 3,684 (94.0) | 258 (93.5) | |
| Regional recurrence | .5a | ||
| Yes | 76 (1.9) | 3 (1.1) | |
| No | 3,844 (98.1) | 273 (98.9) | |
| Systemic recurrence | .7a | ||
| Yes | 314 (8.0) | 20 (7.3) | |
| No | 3,606 (92.0) | 256 (92.7) |
OPM other primary malignancies, BMI body mass index, IDC invasive ductal carcinoma, DCIS ductal carcinoma in situ, ILC invasive lobular carcinoma, SLND sentinel lymph node dissection, ALND axillary lymph node dissection
a
Fisher exact test
b
P value calculated after excluding unknown category
c
Rank sum test